Cabot Corporation reports after the close today with short sellers the most active they have been in months — and options traders moving in the opposite direction.
Short interest has climbed steadily and meaningfully into the print. At 5.7% of the free float, it has risen roughly 16.5% over the past month and 6.4% over the past week alone — a clear acceleration in bearish positioning as the earnings date approached. Days to cover run at 8.5 on the latest official FINRA data, meaning shorts would need more than a week and a half of average volume to exit. Yet the borrow market remains untroubled: cost to borrow holds near 0.47% and availability is ample, so this build reflects conviction rather than a forced squeeze setup.
Options traders are reading the situation differently. The put/call ratio has dropped to 0.30, well below its 20-day average of 0.37 and close to the lowest level of the past year. That is not a defensive posture — it reflects call-side demand and suggests at least part of the market is positioned for an upside surprise. The divergence between a rising short base and a bullish options skew is the sharpest tension heading into today's release.
The analyst backdrop is mixed but leans cautious on valuation. The most recent moves — both from early February — split the room: UBS lifted its target to $81 while holding Neutral, while Mizuho downgraded to Neutral and trimmed its target to $75, near where the stock trades at $75.85. JPMorgan carries an Underweight with a $54 target, a notably bearish outlier. The consensus mean of $77.80 implies minimal upside from current levels, and with the stock essentially flat over the past month, the market has not pre-empted either direction. On valuation, CBT trades at 12x trailing earnings and 7x EV/EBITDA — not stretched for a specialty chemicals company, though the EV/EBITDA multiple has drifted slightly lower over the past 30 days. The dividend score ranks in the 95th percentile, a signal of financial discipline that supports the bull case.
Among correlated peers, EMN and MTX surged 6-8% on the week, diverging sharply from CBT's 1.8% weekly decline. That peer strength makes the recent softness in CBT look stock-specific rather than sector-driven — and puts more pressure on today's numbers to explain it.
The print will test whether the short buildup reflects a genuine fundamental concern about volumes or margins, or whether the call-side optimism in options is the better read on where Cabot's Q2 guidance lands.
See the live data behind this article on ORTEX.
Open CBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
